There were statistically significant differences between MI<50 patients and healthy control group in the prevalence of rs17300539:G>A (AA genotype: 19.3% vs. 0%, p<0.0001) and rs72563731:C>T variants (CC genotype: 81.5% vs. 15.9%, p<0.0001) and between MI<50 and MI≥50 patients in variants: rs17300539:G>A (AA genotype: 19.3% vs. 0.5%, p<0.0001), rs72563731:C>T (CC genotype: 82.1% vs. 60.8%, p<0.0001), rs1501299:G>T (TT genotype: 6.8% vs. 14.9%, p=0.019) and rs822387:T>C (genotype CC: 1.5% vs. 0%, p=0.017).
From a group of DNA samples collected at baseline in a prospective cohort of 14 916 initially healthy American men, we assessed the presence of 5 ADIPOQ genetic variants (rs266729, rs182052, rs822396, rs2241766, and rs1501299) in samples from 600 Caucasian men who subsequently suffered an atherothrombotic event (incident myocardial infarction or ischemic stroke) and from 600 age- and smoking-matched Caucasian men who remained free of reported vascular disease during follow-up (controls).